Oz101 / OzStar Therap - LARVOL DELTA

[VIRTUAL] Oz101, an oligofructose prebiotic, may ameliorate beta cell deterioration associated with long-term sulphonylurea therapy in type 2 diabetes patients: a pilot study (EASD 2021) - "In this pilot trial, in a resource constrained area, adjunctive intake of OZ101 in patients on SU therapy was safe, well tolerated and associated with improved beta cell function and better glycaemic control over 24 weeks. These effects may be partly due to an increase in a number of commensal bacteria previously shown to influence glucose and insulin homeostasis. The lack of dose response may be explained by further changes in the gut microbiome dynamics at higher doses of OZ101."

Clinical • Diabetes • Metabolic Disorders • Type 2 Diabetes Mellitus